Loading insider details...
Beta
Latest Form 4 (Feb 18, 2026): Grant/Award of 33,989 ELVN shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 18, 2026 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 33,989 | n/a |
| Feb 10, 2025 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 20,491 | n/a |
| Jul 2, 2024 | Turnstone Biologics Corp. (TSBX) | Grant/Award | 12,770 | n/a |
| May 20, 2024 | Enliven Therapeutics, Inc. (ELVN) | Sale | 33,300 | $737.3K |
| Feb 16, 2024 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 16,835 | n/a |
| May 19, 2023 | Enliven Therapeutics, Inc. (ELVN) | Exercise/Conversion | 2,125 | $9.1K |
| May 15, 2023 | Verona Pharma plc (VRNA) | Sale | 80,000 | $1.78M |
| Apr 28, 2023 | Verona Pharma plc (VRNA) | Grant/Award | 96,000 | n/a |
| Apr 7, 2023 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 27,567 | n/a |
| Feb 28, 2023 | Enliven Therapeutics, Inc. (ELVN) | Grant/Award | 7,611,458 | n/a |